Published in PLoS Negl Trop Dis on April 28, 2017
Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev (2005) 14.71
The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature (2009) 8.99
Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. Immunity (2007) 5.36
Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha /beta. Proc Natl Acad Sci U S A (2001) 5.21
Increasing incidence of human melioidosis in Northeast Thailand. Am J Trop Med Hyg (2010) 5.10
Mice lacking the type I interferon receptor are resistant to Listeria monocytogenes. J Exp Med (2004) 3.94
Intracellular survival of Burkholderia pseudomallei. Infect Immun (1996) 3.56
An Inv/Mxi-Spa-like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen. Mol Microbiol (2002) 3.23
Structure of the O-chain of the phenol-phase soluble cellular lipopolysaccharide of Yersinia enterocolitica serotype O:9. Eur J Biochem (1984) 3.16
Burkholderia pseudomallei induces cell fusion and actin-associated membrane protrusion: a possible mechanism for cell-to-cell spreading. Infect Immun (2000) 2.70
Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol (2000) 2.41
Genetic tools for select-agent-compliant manipulation of Burkholderia pseudomallei. Appl Environ Microbiol (2007) 2.40
MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol (2007) 2.26
Effects of Burkholderia pseudomallei and other Burkholderia species on eukaryotic cells in tissue culture. Microbios (1998) 2.11
LPS remodeling is an evolved survival strategy for bacteria. Proc Natl Acad Sci U S A (2012) 2.05
Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect Immun (1995) 2.05
Survival of Pseudomonas pseudomallei in human phagocytes. J Med Microbiol (1990) 2.02
The cluster 1 type VI secretion system is a major virulence determinant in Burkholderia pseudomallei. Infect Immun (2011) 2.00
The histopathology of human melioidosis. Histopathology (1995) 1.94
Burkholderia pseudomallei virulence: definition, stability and association with clonality. Microbes Infect (2001) 1.90
Type III secretion system cluster 3 is required for maximal virulence of Burkholderia pseudomallei in a hamster infection model. FEMS Microbiol Lett (2005) 1.89
Modification of the structure and activity of lipid A in Yersinia pestis lipopolysaccharide by growth temperature. Infect Immun (2002) 1.88
Identification of a bacterial factor required for actin-based motility of Burkholderia pseudomallei. Mol Microbiol (2005) 1.83
A horizontal gene transfer event defines two distinct groups within Burkholderia pseudomallei that have dissimilar geographic distributions. J Bacteriol (2007) 1.82
A Burkholderia pseudomallei type III secreted protein, BopE, facilitates bacterial invasion of epithelial cells and exhibits guanine nucleotide exchange factor activity. J Bacteriol (2003) 1.78
The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect Immun (2005) 1.75
Attenuated virulence of a Francisella mutant lacking the lipid A 4'-phosphatase. Proc Natl Acad Sci U S A (2007) 1.64
Toll-like receptor 2 impairs host defense in gram-negative sepsis caused by Burkholderia pseudomallei (Melioidosis). PLoS Med (2007) 1.58
Genetic diversity of Burkholderia pseudomallei isolates in Australia. J Clin Microbiol (2007) 1.56
Burkholderia Pseudomallei is genetically diverse in agricultural land in Northeast Thailand. PLoS Negl Trop Dis (2009) 1.53
Modulating the innate immune response by combinatorial engineering of endotoxin. Proc Natl Acad Sci U S A (2013) 1.45
A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect Immun (2002) 1.45
The Burkholderia pseudomallei type III secretion system and BopA are required for evasion of LC3-associated phagocytosis. PLoS One (2011) 1.38
Activation of Toll-like receptors by Burkholderia pseudomallei. BMC Immunol (2008) 1.33
Cutting edge: a murine, IL-12-independent pathway of IFN-gamma induction by gram-negative bacteria based on STAT4 activation by Type I IFN and IL-18 signaling. J Immunol (2002) 1.32
Burkholderia mallei expresses a unique lipopolysaccharide mixture that is a potent activator of human Toll-like receptor 4 complexes. Mol Microbiol (2006) 1.31
Lipopolysaccharide binding protein binds to triacylated and diacylated lipopeptides and mediates innate immune responses. J Immunol (2004) 1.31
A Burkholderia pseudomallei deltapurM mutant is avirulent in immunocompetent and immunodeficient animals: candidate strain for exclusion from select-agent lists. Infect Immun (2010) 1.26
Molecular and physical characterization of Burkholderia mallei O antigens. J Bacteriol (2002) 1.26
A live experimental vaccine against Burkholderia pseudomallei elicits CD4+ T cell-mediated immunity, priming T cells specific for 2 type III secretion system proteins. J Infect Dis (2006) 1.24
Interferons direct an effective innate response to Legionella pneumophila infection. J Biol Chem (2009) 1.19
Synergy between TLR2 and TLR4: a safety mechanism. Blood Cells Mol Dis (2002) 1.18
Pseudomonas (Burkholderia) pseudomallei in Thailand, 1964-1967: geographic distribution of the organism, attempts to identify cases of active infection, and presence of antibody in representative sera. Am J Trop Med Hyg (2000) 1.11
Extraction and characterization of lipopolysaccharide from Pseudomonas pseudomallei. FEMS Microbiol Lett (1992) 1.10
Glyphosate resistance as a novel select-agent-compliant, non-antibiotic-selectable marker in chromosomal mutagenesis of the essential genes asd and dapB of Burkholderia pseudomallei. Appl Environ Microbiol (2009) 1.09
Attachment of Burkholderia pseudomallei to pharyngeal epithelial cells: a highly pathogenic bacteria with low attachment ability. Am J Trop Med Hyg (1999) 1.07
An ultrastructural study of the phagocytosis of Burkholderia pseudomallei. Microbios (1998) 1.05
Protein detection and quantitation technologies for gel-based proteome analysis. Methods Mol Biol (2009) 1.02
Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry of lipopolysaccharides. Methods Mol Biol (2000) 1.01
Chemical characterization of two lipopolysaccharide species isolated from Rhizobium loti NZP2213. Arch Microbiol (1995) 1.01
Structural and biological diversity of lipopolysaccharides from Burkholderia pseudomallei and Burkholderia thailandensis. Clin Vaccine Immunol (2009) 1.01
The genetic and molecular basis of O-antigenic diversity in Burkholderia pseudomallei lipopolysaccharide. PLoS Negl Trop Dis (2012) 0.99
Role for the Burkholderia pseudomallei capsular polysaccharide encoded by the wcb operon in acute disseminated melioidosis. Infect Immun (2009) 0.99
Stable, site-specific fluorescent tagging constructs optimized for burkholderia species. Appl Environ Microbiol (2010) 0.99
Human lipopolysaccharide-binding protein (LBP) and CD14 independently deliver triacylated lipoproteins to Toll-like receptor 1 (TLR1) and TLR2 and enhance formation of the ternary signaling complex. J Biol Chem (2013) 0.96
Variable virulence factors in Burkholderia pseudomallei (melioidosis) associated with human disease. PLoS One (2014) 0.95
Characterization of Burkholderia pseudomallei Strains Using a Murine Intraperitoneal Infection Model and In Vitro Macrophage Assays. PLoS One (2015) 0.93
Survey of innate immune responses to Burkholderia pseudomallei in human blood identifies a central role for lipopolysaccharide. PLoS One (2013) 0.93
Antibodies from patients with melioidosis recognize Burkholderia mallei but not Burkholderia thailandensis antigens in the indirect hemagglutination assay. J Clin Microbiol (2005) 0.92
Comparative Burkholderia pseudomallei natural history virulence studies using an aerosol murine model of infection. Sci Rep (2014) 0.89
Detection of Burkholderia pseudomallei O-antigen serotypes in near-neighbor species. BMC Microbiol (2012) 0.89
The Burkholderia pseudomallei Δasd mutant exhibits attenuated intracellular infectivity and imparts protection against acute inhalation melioidosis in mice. Infect Immun (2011) 0.89
Phylogenomic Analysis Reveals an Asian Origin for African Burkholderia pseudomallei and Further Supports Melioidosis Endemicity in Africa. mSphere (2016) 0.88
Consensus on the development of vaccines against naturally acquired melioidosis. Emerg Infect Dis (2015) 0.88
Mechanisms of intrinsic resistance to antimicrobial peptides of Edwardsiella ictaluri and its influence on fish gut inflammation and virulence. Microbiology (2013) 0.84
Thematic review series: the immune system and atherogenesis. Bridging the innate and adaptive immune systems. J Lipid Res (2005) 0.81
Immunomodulatory effects of Yersinia pestis lipopolysaccharides on human macrophages. Clin Vaccine Immunol (2009) 0.80
Macroautophagy is essential for killing of intracellular Burkholderia pseudomallei in human neutrophils. Autophagy (2015) 0.79
Characterization of the murine macrophage response to infection with virulent and avirulent Burkholderia species. BMC Microbiol (2015) 0.79
Differential Toll-Like Receptor-Signalling of Burkholderia pseudomallei Lipopolysaccharide in Murine and Human Models. PLoS One (2015) 0.78
Genomic characterization of Burkholderia pseudomallei isolates selected for medical countermeasures testing: comparative genomics associated with differential virulence. PLoS One (2015) 0.78
LPS quantitation procedures. Methods Mol Biol (2014) 0.77
Preferential solvation of glucose and talose in water-acetonitrile mixtures: a molecular dynamics simulation study. Phys Chem Chem Phys (2010) 0.76
Development of Immunoassays for Burkholderia pseudomallei Typical and Atypical Lipopolysaccharide Strain Typing. Am J Trop Med Hyg (2016) 0.76